Investor Sentiment Wavers Despite Strong Clinical Results for Beam Therapeutics Beam Therapeutics’ stock faces heightened volatility, with short interest rising over 27% this month despite favorable analyst ratings and positive BEAM-302 trial results. Insiders, including the CEO and president, have trimmed their holdings, while 23.7% of shares are now sold short, signaling mixed confidence among market participants.34